{"disease":{"id":"cushings-disease","name":"cushings disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01504399","title":"Rhinological Outcomes in Endonasal Pituitary Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"St. Joseph's Hospital and Medical Center, Phoenix","has_results":false},{"nct_id":"NCT02310269","title":"Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease","phase":"","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"RECORDATI GROUP","has_results":true},{"nct_id":"NCT02180217","title":"Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01915303","title":"Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":68,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01331239","title":"Safety and Efficacy of LCI699 in Cushing's Disease Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}